Efficacy and Safety of Switching to DTG/3TC Dual Therapy From B/F/TAF Among Older Adults ≥60 Years

0503

Loice Achieng Ombajo[1,2], Joseph Nkuranga[1,2], Victor Omodi[1,2], Zian Muikamba[1,2], Edwin Otieno[1,2], Jeremy Penner[2,3], Michelle Kisare[4], Simon Wahome[5], Florentius Ndinya[6], Ricky Echesa[1,2] For the Sungura study group

[1]Department of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, Kenya, [2]Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya, [3]Department of Family Practice, University of British Columbia, Vancouver, Canada, [4]ViiV HealthCare, London, UK, [5]Kenyatta National Hospital, Nairobi, Kenya, [6]Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, Kenya

BACKGROUND

- Use of 2DR such as dolutegravir/lamivudine (DTG/3TC) minimises exposure to NRTIs
- This reduces drug toxicities that overlap with co-morbidities common in older persons living with HIV.
- The efficacy of DTG/3TC has been demonstrated in persons with no history of prior virological failure.
- We evaluated the efficacy and safety of switching older adults from B/F/TAF to DTG/3TC.

METHODS

- The Sungura Study (NCT06444620) is an open-label, single arm, 96-week study at two sites in Kenya.

Figure 1: Overview of the Sungura Study



- The primary endpoint was the proportion of participants with viral load ≥50 copies/mL at 48 weeks using the FDA snapshot algorithm.

RESULTS

- Between July and Sep 2024, 197 participants were enrolled and treated and included in the ITT-E analysis.

Table 1: Baseline Characteristics

Characteristic	Frequency (N = 197)
Age (years), median (min, max)	66.1 (61.9, 81.1)
Sex: Female	97 (49.2%)
Body-mass index (kg/m^2), median (IQR)	26.4 (23.0, 29.4)
Time on ART (years), median (IQR)	12.0 (9.5, 12.4)
Hypertensive at baseline	138 (70.1%)
Diabetes/Hyperglycemia at baseline	32 (16.3%)
Dyslipidemia at baseline	46 (23.4%)
Grade 2-3 CrCl abnormality	166 (84.3%)
Grade 2-4 lipid abnormality	114 (57.9%)
Grade 2-4 FBG abnormality	28 (14.3%)
ASCVD risk score category	
Low risk (<5%)	1 (0.5%)
Borderline risk (5% to 7.4%)	21 (10.7%)
Intermediate risk (7.5% to 19.9%)	128 (65.3%)
High risk (≥20%)	46 (23.6%)

All participants on DTG/3TC dual therapy were virally suppressed at week 48 in an aging population living with HIV

Baseline and incident comorbidites were high

RESULTS contd…

- HBcAb was positive in 92 participants, all of whom had HBsAb levels ≥ 10 U/ml. Baseline prevalence of co-morbidities was high
- At week 48, 197 participants remained on DTG/3TC and none (0/197) had HIV viral load ≥50 copies/mL
- One participant required switch to TDF/3TC/DTG + DTG on the week 48 visit due to pulmonary tuberculosis requiring treatment with rifampicin.

Figure 2: Incident Comorbidities and Weight Change



- There were 11 serious adverse events with none related to the study drug (table 2).
- One participant with HBcAb positive at baseline had a grade 2 AST abnormality at week 48, the ALT was normal with no other features of hepatitis.
- The median change in 10-year ASCVD risk score was 0.0% (IQR -1.7 to 2.9).

PLAIN LANGUAGE SUMMARY

A number of people aged 60 years or older with HIV had other new or existing long-term health conditions. A two-drug treatment option combining dolutegravir and lamivudine effectively maintained viral suppression after 48 weeks. This simpler treatment may be a good option for older adults with HIV.

Table 2: Adverse Events

	Total (n = 197)
Any AE (total number of AEs)	**205**
AE occurring in > 5% of participants	
New or worsening dyslipidemia	30 (15.2%)
Worsening creatinine clearance	23 (11.7%)
URTI	16 (8.1%)
Malaria	14 (7.1%)
AE leading to study drug discontinuation – total (%)	**1 (0.5%)**
Tuberculosis	1 (0.5%)
Treatment-related Serious AEs total (%)	**0 (0.0%)**
Serious AEs (%)	**11 (5.6%)**
Central cord syndrome after RTA	1 (0.5%)
Peptic ulcer disease	1 (0.5%)
Acute kidney injury	1 (0.5%)
Right ankle fracture after RTA	1 (0.5%)
Osteoarthritis requiring total knee replacement	1 (0.5%)
Gastroenteritis	1 (0.5%)
LRTI	1 (0.5%)
Malaria	1 (0.5%)
Urethral stricture requiring surgical intervention	1 (0.5%)
Diabetic wound with cellulitis	1 (0.5%)
Pelvic malignancy	1 (0.5%)
Grade 3 or 4 laboratory abnormalities – total (%)	**66 (33.5%)**
Total cholesterol	5 (2.5%)
LDL	10 (5.1%)
Triglycerides	2 (1.0%)
Creatinine Clearance	45 (22.8%)
Fasting Glucose	4 (2.0%)

CONCLUSION

- At week 48, there was no virologic failure or withdrawal from the Sungura study.
- Co-morbidities were common, highlighting additional considerations for selecting antiretroviral agents for older populations.

ACKNOWLEDGEMENT

This is an investigator-initiated trial funded by ViiV Healthcare and sponsored by the University of Nairobi. We thank the study participants, study sites and personnel at Jaramogi Oginga Odinga Teaching and Referral Hospital and Kenyatta National Hospital, and the Ministry of Health through the National AIDS and STI Control Program

CONTACT

loisea@uonbi.ac.ke

Disclaimer

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.